Trial Profile
A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Isatuximab (Primary)
- Indications Carcinoma; Glioblastoma; Head and neck cancer; Liver cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 10 May 2023 Status changed from completed to discontinued.
- 08 Jun 2022 Status changed from active, no longer recruiting to completed.
- 29 May 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database.